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Abstract: Significant improvement of solubilization kinetics of poorly-soluble vinpocetine was obtained through a mechanochemical activation process in presence of micronized crospovidone. Drug-to-polymer weight ratio and milling time variables resulted to have statistically significant impacts on the activation of the product. The complete amorphysation was obtained in the coground with the highest crospovidone contents (>80% wt), milled for the longest time (180 min). An ad hoc software was then used to calculate the dimensions of the drug crystallites in the samples on the basis of the calorimetric data. The thermal analyses were then accompanied and confirmed by an extensive solid state characterization, performing X-ray diffraction, Raman imaging/spectroscopy, DRIFT and SS-NMR spectroscopy, followed by laser diffraction and solubilization kinetics tests. All the analyses agreed on attesting the progressive loosing of crystalline structure of the drug when increasing milling time and amount of polymer in the formulations. This activated status of the drug, that resulted to be homogeneously distributed on the coground sample and stable for at least 1 year, was reflected on favorable solubilization kinetics. The in vivo studies on rats revealed that coground systems promoted a five-fold higher oral bioavailability enhancement in comparison to a commercial formulation (Vimpocetin® 5 mg Capsules, Pharma). 





Vinpocetine (VIN) is a semi-synthetic derivative of the Vinca minor L. alkaloid vincamine1. VIN is a poorly water-soluble base-type drug (pKa=7.1).2 In the pH range between 1.2 and 8.0, VIN solubility enhanced by a reduction in pH and showed an approximately linear relationship between the logarithm of the solubility and pH.3 It has been shown to improve cerebral circulation and metabolism in the treatment of various types of cerebrovascular circulatory disorders, e.g. cerebral infarction, cerebral hemorrhage residual and cerebral arteries cirrhosis, etc. VIN was introduced in clinical practice in Hungary for the treatment of cognitive disorders and related symptoms.4 It is mainly used as oral dosage forms, usually in tablets, containing 5 mg of active ingredient, with a daily dosage regimen that can vary between 5mg_3/day to 20mg_3/day.5 However, existing formulations exhibit poor bioavailability (~6.7%)6-7 and poor absorption.8 Due to its scarce aqueous solubility and wettability, and extensive metabolism during first pass. An oral formulation with a high degree of oral absorption would, therefore, be highly desirable. 
Up to now the strategies that have been carry out to enhance VIN oral bioavailability have been mainly focused in two directions: on the one hand, to prepare liquid and solid self emulsifying systems, thanks to its good solubility in oils9-11 and, on the other hand, thanks to its molecular weight/steric encumbrance and lipophylic nature to its inclusion in cyclodextrins.8, 12-19 
In this study an alternative approach has been attempted, based on the preparation of binary coground systems with micronized crospovidone (PVP-CL) using an optimized mechanochemical activation process conducted in planetary mill. This approach has been previously successfully applied in the case of another poorly-soluble phytochemical, the Sylimarine, from Milk thistle extract.20-21 




Vinpocetine was kindly gift from Linnea SA (Riazzino-Locarno, CH). 
Micronized crospovidone (PVP-CL®-M) was purchased by BASF/Euphar (Milano, Italy). All other chemicals, of analytical grade, and solvents of HPLC grade, were provided by Carlo Erba (Milan, Italy). Vimpocetin® 5 mg capsules were from Pharma, Hungary and contained the following ingredients: 5 mg of vinpocetine, lactose and magnesium stearate. 

Preparation of coground mixtures
Drug and crospovidone were coground in several drug -to- polymer weight ratios according to the experimental plan (Table I) in a planetary mill Fritsch P5 (Pulverisette, Contardi Fritsch s.r.l., Milan, Italy). The planetary mill was equipped by four agate cylindrical grinding chambers (internal height Hv=2.6 cm, internal radius Rv=3.2 cm, internal volume = 27.5 cm3) adopting agate balls (diameter 2.2 cm) as grinding media.
Five grams batches, previously blend in the suitable proportions (according to the experimental plan below reported) with a stainless steel spatula, were simultaneously coground. The following operative conditions were selected on the basis of a previously published ah hoc mathematical model: 21 maximum velocity (10,000 rpm), bowl loading (5 g), number of grinding media (6 agate balls). The grinding procedure was pursued for different milling times, according to the experimental plan below reported, stopping every 15 min for homogeneously mixing the mass with a stainless steel spatula. Two factors, a process variable (milling time- x1) and a formulation variable (drug to polymer wt ratio- x2), were selected for investigation. Each factor was considered in different experimental levels: 5 experimental levels for milling time (60, 90, 120, 150, 180 min) and 6 levels for drug-to-polymer weight ratio (1:1; 1:2; 1:3; 1:4; 1:7; 1:10). The effect of these variables on a solid state coground characteristic (melting enthalpy- y1) was evaluated. Preliminary experiments were carried out to select the experimental levels. The experimental plan (shown in table 1) was designed using nemrodw program22 and the statistical analysis was performed by standard R package.23 To reduce systematic errors experiments were completely randomized. 
Preparation of physical mixtures
For comparison purposes, physical mixtures (PM) were prepared by manually mixing drug and polymer using the same weight ratios as the coground systems.
Differential scanning calorimetry (DSC)
Calorimetric analyses were carried out using a differential scanning calorimeter (Mod. TA 4000, equipped with a measuring cell DSC 20 Mettler). The calibration of the instrument was performed with indium, zinc and lead for the temperature, and with indium for the measurement of the enthalpy. Samples, containing about 2 mg of vinpocetine were placed in pierced aluminum pans and heated at a scanning rate of 10°C per min from 30 to 170°C, under air atmosphere. 
Determination of Nanocrystal fraction and size distribution
The estimation of nanocrystal (Xncr) and amorphous (Xa) drug fraction jointly with the evaluation of nanocrystal size distribution characterizing co-ground systems were led according to Coceani et al.24 Briefly, this approach starts from the results of the Brun and co-workers theory25 according to which the following relations holds among nanocrystal melting temperature (Tmr), specific enthalpy (hmr) and radius Rnc: 
										(1)
								(2)
where Tm is the infinite radius crystal melting temperature, lv and sl are, respectively, liquid drug-vapor and solid drug-liquid drug surface tensions while s and l are, respectively, solid and liquid drug density. Eq.(1) is based on the hypothesis that the liquid-vapor curvature radius (Rlv) is infinite, this happening when the crystal is embedded in a large amount of amorphous drug. Thus, crystal melting occurs inside a large amount of liquid phase. On the contrary, eq.(2) relies on the hypothesis that Rlv is coincident with Rnc, this occurring when many crystals are packed together and, upon melting, each crystal is surrounded by a thin liquid film. Thus, while eq. (1) applies for low nanocrystal fractions (Xncr ≈ 0), eq. (2) holds in the opposite case (Xncr ≈ 1). As in real systems nanocrystals can undergo melting in both the above mentioned conditions, a reasonable way accounting for this mixed condition is weighing the contribute of eqs.(1) and (2) right hand side terms according to Xncr as follows:
					(3)
In order to solve Eq. (3), the approach of Zhang and co-workers26 expressing the hmr dependence on Tmr and Rnc was adopted:
								(4)
where hm∞ is the specific melting enthalpy referred to the infinite radius drug crystal, Cp is the difference between the liquid and the solid drug specific heat capacity at constant pressure. As Cp is almost temperature invariant, the third term on the right hand side of eq. (4) can be approximated by Cp(Tm∞ - Tmr) without relevant errors. The determination of hmr(Rnc), Tmr(Rnc) and Xncr is achieved by means of an iterative, numerical, simultaneous solution of eqs.(3)-(4). Starting from a first guess value for Xncr (typically, Xncr = 0) eqs. (3)-(4) are solved to have a first evaluation of the functions hmr(Rnc), Tmr(Rnc). Then, Xncr is recalculated according to:
								(5)
where hcg is the experimentally determined co-ground system melting enthalpy referred to the system unit mass (drug plus polymer) and evaluated at Tmr (as our carrier, the polymer, is amorphous, hcg is only due to drug melting), d is the drug mass fraction characterizing both the physical mixture and the co-ground systemhmix is the melting enthalpy referred to the physical mixture (drug plus polymer) unit mass and evaluated at Tm∞ and d while hr and hT are the specific enthalpy corrections (referred to pure drug unit mass) representing, respectively, the nanocrystal melting enthalpy reduction due to nanocrystal radius reduction and melting temperature reduction (see, respectively, the second and third term in the right hand side of eq.(4)). hr and hT are determined in the simultaneous solution of eqs.(3)-(4). As our coground systems did not show macrocrystal melting, the amount of amorphous drug fraction (Xa) is simply given by:
											            (6)
The determination of nanocrystals size distribution relies on the knowledge of hmr(Rnc), Tmr(Rnc), Xncr and on the relation occurring among the volume dVr occupied by nanocrystals of radius lying in the range Rnc – (Rnc + dRnc) and their specific melting enthalpy (J/Kg) hmr, melting enthalpy (J) Hmr and density s:
							(7)
where t is time,  is the signal registered by DSC (mW) and v is the DSC heating speed (°C/min). The determination of nanocrystals differential volume distribution (f(Rnc)) can be computed as:										(8)
where  and  represent, respectively, the maximum and minimum value assumed by Rnc.
X-ray Powder Diffraction Studies (XRD)
Solid state of the samples was studied by means of XRD technique using a D500 (Siemens, Munich, Germany) diffractometer with Cu-K radiation (1.5418 Å), monochromatized by a secondary flat graphite crystal. The current used was 20 mA and the voltage 40 kV. The scanning angle ranged from 5 to 35° of 2, steps were of 0.05° of 2, and the counting time was of 5 sec/step.
Transmission Electron Microscopy (TEM)
TEM images were taken on a Philips EM 208 (Philips, Eindhoven, NL)  at an accelerating voltage of 100 kv.
Diffuse Reflectance Infrared Fourier Transform spectroscopy (DRIFT)
Diffuse Reflectance Infrared Fourier Transform spectra were obtained on a FT-IR spectrometer (FT-IR Perkin Elmer Spectrum One, Monza, Italy) using the abrasive pad method. The samples (drug, carrier, 1:4 and 1:10 wt coground, and corresponding PM) were previously added to anhydrous KBr (FT-IR grade) in a 1:15 weight ratio (sample to KBr) and gently ground using a pestle, thus avoiding solid transition possibly induced by extended grinding and yet sample particles are small and evenly dispersed. The scanning range was 450–4000 cm-1 and the resolution was 4 cm-1, scan number was 8 and scan speed 0.20 cm/s.
Raman imaging/spectroscopy 
Raman spectra and images were acquired for coground composite, physical mixture and pure components using an inVia Raman system (Renishaw plc, Wotton-under-Edge, UK), equipped with a 300 mW diode NIR laser emitting at 785 nm (Renishaw) and a ProScanTMII motorized stage (Prior, Cambridge, UK). The laser was focused on the sample (consisting of 300mg tablets with flat surfaces, prepared from physical and coground mixtures having different drug-polymer ratios, and from pure components) by a 50X objective (0.75 N.A.). To ensure a better sampling for each tablet by taking into account local variations in composition, an area of 84x84 μm was mapped with a grid of 2.8 μm (corresponding to 900 spectra per map) for each sample, using the StreamlineTM fast imaging configuration and the WiRE 3.1 software (Renishaw), with an total collection time of 13 min/map. Raman maps were then pre-processed (cosmic rays removal and baseline correction) and analyzed with the HyperSpec software package;27 an average spectrum was calculated for each map, and images depicting the intensity ratio between VIN 1610 cm-1 band and the PVP-CL 1668 cm-1 band were produced. 
Solid-state nuclear magnetic resonance spectroscopy(SS-NMR)
NMR spectra of solid samples were recorded on Varian Unity Inova 300 MHz NMR spectrometer equipped with 5 mm Magic Angle Probe and Varian NMR System 600 MHz NMR spectrometer equipped with 3.2 mm NB Double Resonance HX MAS Solids Probe. Larmor frequencies of protons and carbon nuclei were 302.98 MHz and 76.19 MHz at 300 MHz NMR spectrometer, respectively and 599.77 MHz for protons at 600 MHz NMR spectrometer. The proton and 13C CP/MAS NMR spectra were externally referenced using adamantine or hexamethylbenzene (HMB), respectively. All samples were spun at the magic angle with 5 kHz spinning frequency during 13C measurements at 300 MHz NMR spectrometer and 20 kHz during 1H measurements at 600 MHz NMR spectrometer. The proton spectra were acquired using spin echo sequence. Repetition delay in all experiments was 5 s. The number of scans was 16. The pulse sequence used for acquiring the 13C CP/MAS spectra was a standard cross-polarization MAS pulse sequence with high-power proton decoupling during acquisition. Repetition delay in all experiments was 3 s and the number of scans was between 8000 and 27000 depending on the signal-to-noise ratio.
Particle size measurements
Particle size measurements of the coground were determined using a laser light scattering technique (Malvern Particle Size Analyzer Model No. 2000, Malvern, UK). Before analysis, about 10 mg of composite were dispersed by sonication in 100 ml of water. 
Release kinetics
Release tests, performed in triplicate, were led in 150 cm3 of 0.2 M KH2P04/0.2 M NaOH (pH 7.4) at 37°C. At this pH value the solubility was 1.6 mg/L. At time zero, a suitable amount of sample (as a pure drug or in binary systems) to give 5 mg of active was added to the release environment. Uniformity conditions were ensured by means of an impeller (rotational speed 200 rpm). The use of a fiber optic apparatus (HELLMA, Italy), connected to a spectrophotometer (ZEISS, Germany, wavelength 270.19 nm), allowed the determination of vinpocetine concentration without perturbing the release environment (each release test lasted 180 minutes). Moreover, this methodology allowed to easily overcome the problem connected to drug concentration measurement in presence of a dispersion of solid particles. Indeed, while the maximum vinpocetine absorption occurred at 270.19 nm, the scattering effect due to polymeric particles uniformly occurred at every wavelength. Accordingly, the real absorbance related to vinpocetine concentration was the difference between the absorbance measured at 270.19 nm and that measured at 500.49 nm (at 500.49 nm vinpocetine did not absorb). Non-sink conditions were attained in release environment. Results were the average of three replicates and standard deviations did not exceed 5%.
In vivo absorption studies
Experiments on animals complied with the Italian D.L. n. 116 of 27 January 1992 and associated guidelines in the European Communities Council Directive of 24 November 1986 (86/609 ECC).
Animals used were male Sprague-Dawley rats (450 g weight) and were supplied by Centro Servizi Polivalenti di Ateneo (University of Trieste). Rats, with free access to water, were fasted overnight. Each experimental formulation was administered to 4 rats by gastric gavage as 2 ml of aqueous suspensions (corresponding to a dose 11 mg/kg of vinpocetine). 
Blood samples (600 l) were collected using the “cannulated” tail artery method28 in heparinized tubes at 30, 60, 90, 120, 180 and 360 min after administration. Blood samples were added of 66l of a 40 mM tetrasodium EDTA solution, centrifuged at 1500 rpm for 10 min and plasma was separated and immediately frozen at -20°C, and stored at this temperature till the analysis.
Assays of Vinpocetine in powder and plasma samples
HPLC Sample preparations
For the determination of the drug content in the physical mixtures, coground systems and commercial sample the procedure was the following: a suitable amount of powdered sample was accurately weighted and transferred to a 100 ml volumetric flask and diluted with acetonitrile. The mixture was sonicated for 10 min and then filtered through a syringe filter (RC 0.45 µm, Phenomenex, Castel Maggiore, Bologna) to remove any particle. The first 5 µl of the filtrates were discarded and the subsequent were collected. Then, an appropriate amount of the filtrate was diluted with acetonitrile and assayed by a validated high pressure liquid chromatographic (HPLC) with mass spectrometry (MS) detection method,29 later described into details.
As for the determination of vinpocetine in plasma samples the following procedure was adopted: briefly, to 200 l plasma, 600 l methanol were added, and the mixture was vortexed for 10 min. After centrifugation (5000 rpm for 6 min), 5 l of the organic solution was injected. The vinpocetine determination was carried out using the same HPLC-MS method.
HPLC analysis 
The HPLC system consisted of a Varian LC212 with a 500-MS IT mass detector. The chromatographic separation was conducted at room temperature, using a Varian C 18 Polaris column (3 m, 2.0 x 50 mm). The mobile phase was composed of water with 0.1% formic acid (solvent A) and acetonitrile (solvent B). Isocratic conditions were used with A 57: B 43, total run time was 3 min. The flow rate was 200 l/min. 
MS conditions: ESI (positive mode), needle voltage 5350 V, drying gas temperature was 400° C, capillary voltage was set to 100 V and RF loading was set to 100%, nebulizer gas pressure was 25 psi; drying gas pressure was 15 psi. The detector was set to monitor m/z= 290-390. 
The calibration curve for vinpocetine ranged from 14.5 to 142.40 ng/ml (plasma). The limit of quantification was 2 ng/mL. The precision and accuracy were under 3% for all calibration points.
Pharmacokinetic analysis
Pharmacokinetic parameters of coground, physical mixtures and commercial tablets were calculated on the plasma curves. The area under the plasma concentration-time curve extrapolated to the last sampling time at which a quantifiable concentration is found (AUClast) was calculated using the log-linear trapezoidal method. Time and value of maximum concentration (tmax and Cmax, respectively) were reported as observed. The relative bioavailability after oral administration (Frel) was calculated in Eq. 1: 
									(9)
Pharmacokinetic analysis was performed using WinNonlin Version 2.1 (Pharsight Corporation, Mountain View , CA ) software. 

results and discussion
As previously stated, the aim of the work was to employ the mechanochemical activation process for enhancing the solubility of vinpocetine, thus possibly improving its oral bioavailability. In this case, the phytochemical drug was coground with a crosslinked polymer, PVP-CL, in different drug to polymer weight ratios and using different milling times, according to an experimental plan (Table 1), to check the effect of these formulation and process variables on the characteristics of the coground product. The process was conducted in a Fritsch P5 planetary mill that is particularly suitable for its lab scale for performing a study of screening among variables. In this apparatus the solid state activation is mainly achieved by the creation of shearing interactions, as a result of the rolling of ball elements on the wall of the grinding container. As the experimental response of the experimental plan, the drug melting enthalpy in the coground system (determined by DSC analysis) was considered. It is in fact well known that the melting enthalpy is related to crystallinity of the sample, and hence this parameter can be very useful to check possible structural changes in the product evidence of the “activation” of the product. As a first step, it is hence very important to select the optimal process and formulation conditions for reducing drug melting enthalpy through an appropriate experimental design. 
Due to the fact that single runs were carried out, a full two-way ANOVA model with interaction was not adoptable. In fact, the number of observations is equal to the number of parameters. Actually, the parameters could be estimated, but no further inference would be possible. In this case, the literature suggests the graphical approach to evidence the interaction between independent variables.30 
As it can be observed from Fig.1, the drug melting enthalpy Y decreased for growing milling times T, and slightly faster for higher drug-to-polymer weight ratio R. In both cases the curves were not perfectly parallel.
For the purposes of the present study and for the sake of simplicity, no interactions were assumed. The following model without interaction was thereby fitted:
                               Yij  = ijij						
where  is the ground state of Y, and iand j are the effect of milling time T and drug-to-polymer weight ratio R, respectively. The results obtained using the standard R package (R Development Core Team)23 is listed in Table 2.
From the overall analysis of the Fig.1 and Table 2 it appears that the most significant changes of drug solid state are obtained with longest milling times (150 and 180 min) and with all the performed variations of coground composition.
This behavior is quite reasonable. In fact, from one hand vinpocetine can be easily get trapped into the amorphous physically crosslinked polymer as the polymer amount increased. Once embedded, it would be probably stabilized in the metastable amorphous or nanocrystalline form. From the other hand, the time factor is also important: as the milling time increased, a higher quantity of mechanical energy due to the tangential mechanical strain of the planetary mill is transferred to the material, thus inducing more pronounced structural changes in the sample.
For brevity, the systems prepared with the longest milling time (180 min) will be selected for further considerations.
Looking at the DSC traces of the coground systems (Fig.2), in comparison to native drug and simple physical mixtures, the following considerations can be also drawn.
The pure drug showed an endothermal event at 149.6° (Fig.2a-A), whilst the amorphous polymer exhibits only an endothermic hump due to its dehydration upon heating (Fig.2a-B). The physical mixtures prepared in different drug to polymer ratios showed a complete absence of interactions among components. In fact, the thermograms (Fig. 2, traces from C to H) are the sum of the thermal events of the drug and the polymer, whereas the drug melting enthalpy is proportional to the drug content in the systems. The DSC traces of the systems coground in different drug-to-polymer weight ratios for the same milling time (180 min) are compared in figure 2b. In this image the vinpocetine melting peak noticeably shifted to lower temperatures when increasing the amount of PVP-CL. Further, the drug melting event is characterised by a progressive broadening of the endotherm and by a progressive reduction of relative enthalpy with increased proportions of carrier. In addition, the effect of milling time on the drug melting event can be seen in fig. 2c (for the sake of brevity only the 1:4 wt fraction is reported) where a progressive reduction of drug melting enthalpy and drug melting peak can be observed with increasing the milling time. The decreasing and the broadening of the melting peak indicate the formation of  nanocrystalline structure, whereas the decreasing of melting enthalpy indicates the presence of amorphous vinpocetine.31 Hence, it would be interesting on the basis of the DSC features to ascertain not only the degree of crystallinity reached by each coground sample, but also the size of drug crystallites and their distribution in each sample.
These information were obtained by DSC data analysis according to the home-made MELTINGDSC software whose principles were briefly presented in the “Determination of Nanocrystal fraction and size distribution” paragraph. The resulting percentages of amorphous and/or nanocrystalline drug in the coground systems are reported in Table 3, whilst the differential distribution of the crystal radius in the composites depending on their composition is depicted in Fig.3.
In the coground systems treated for 180 min, the percentage of amorphous drug increased as the polymer content augmented whilst that of nanocrystalline drug simultaneously diminished. Further, the drug melting point and the drug melting enthalpy progressively diminished as the polymer content increased. These thermal phenomena were thus evidence of the progressive destructuration of crystalline lattice of vinpocetine and of its progressive conversion with increased polymer content. The complete destructuration of drug crystal lattice is achieved with the 1:10 wt system, appearing completely amorphous (Xa =99.90%).
As for the differential distribution of the crystal radius in the composites in the various compositions, from Figure 3 it appears that while peak frequency is almost constant (around 5 nm), size distribution is progressively narrowing as polymer content increased. This underlines the importance played by polymer content in getting a homogeneous system (from the nanocrystal size distribution point of view). Probably, this behavior can be explained by the polymer stabilization action that should be proportional to polymer content.
To verify the achievement of the aim of the research, so to enhance the oral vinpocetine bioavailability, the subsequent step consisted in the evaluation of the in vitro dissolution performances of the coground systems using the solubilization kinetics method in comparison to the physical mixtures and to the pure vinpocetine (Figure 4). In particular, in the light of the aforementioned statistical analysis, the systems treated for the longest time and having 6 different polymer content were analyzed. 
The simple physical mixtures, independently from the polymer content, displayed dissolution profiles not significantly different and almost super-imposable to that of pure drug (see Fig. 4, where for brevity, only 1:10 wt PM is reported). Conversely, the activated state of the coground systems, demonstrated by previous thermal analyses, was reflected in a remarkable improvement of dissolution performance in comparison to the physical mixtures and to the pure drug. In fact, less energy is required to dissolve the “activated” drug (nanocrystalline and/or amorphous drug) with respect to the original stable crystalline phase. 
Among different coground systems, the best performances both in terms of rate and extent of dissolution can be achieved from the systems containing more than 80% wt of PVP-CL. These mechanochemically treated systems after 180 min showed an increase of the solubilized amount ranging from 124 to 190 fold, depending on the composition, with absence of supersaturation phenomena. Amongst the 3 best performing coground systems, the 1:4 and 1:10 wt, representing the compositions at the boundaries, were selected for further characterizations.
In particular, the following analyses were performed to complete the solid state investigation: X-ray diffraction, DRIFT, Raman imaging/spectroscopy, and SS-NMR analysis.
Figure 5 reports the diffractograms of the 1:4 and 1:10 wt coground systems compared to the PM and the raw materials. Besides the complete lack of peaks and the halo pattern, typical of amorphous materials, detected in the pattern of PVP-CL (Fig.5f), the drug shows intense reflections (Fig.5a) indicating its crystalline nature. In particular, the diffractogram is very similar to that previously reported for vinpocetine by Ribeirio et al.16: the major peaks are appearing in the range between 10 and 25° of 2θ.
Observing the XRD patterns of the 1:4 active to polymer wt ratios binary system coground for 3 h the major drug reflections are still detectable (Fig.5b). When comparing to the corresponding PM (Fig.5c), a dramatic reduction of their intensity, a slight broadening of the reflections, and a remarkable underneath scattering phenomenon can be noticed. These facts are evidence of the partial conversion of the original crystal lattice into an amorphous and/or nanocrystalline phase, in agreement to previous thermal analyses. Interestingly, the XRD pattern 1:4 wt coground (Fig.5b) revealed that co-grinding did not lead to the formation of polymorphs as the peaks are exactly those related to pure VIN (see Fig.5a).
XRD analysis also testified that in the case of the coground system 1:10 VIN:PVP-CL wt the complete amorphysation was reached (Fig.5d). In this pattern two large humps can be recognized, resulting from the polymer that shows its apices at about 12 and 22 ° 2θ (see Fig. 5f). On the contrary, no peaks referred to VIN can be detected (see Fig.5a). As in the XRD pattern of the 1:10 wt PM (Fig. 5e) the VIN characteristics peaks emerged, VIN peaks disappearing in the XRD pattern of the coground system 1:10 VIN:PVP-CL wt can not be attributed to the simple attenuation of the drug signals due to the high amount of crospovidone. 
Further, the same coground samples (1:4 and 1:10 wt)  were assayed by TEM analysis. The 1:4 wt coground sample (Fig. 6a) appeared as spherical structures formed by the polymer embedding the active. In particular, the crosslinked network of PVP-CL can be clearly seen together with the nanocrystalline drug formations (dark structures) having dimensions compatible with those previously calculated by the MELTINGDSC program. Once again in agreement to previous characterizations, the 1:10 wt coground samples appeared completely amorphous (Fig. 6b). It can be concluded that TEM pictures provided direct evidence of the existence of nanocrystalline phase only in the case of 1:4 wt composite.
The characterization was then pursued by means of DRIFT technique, since vibrational changes can serve as probes of intermolecular interactions in solid materials. For brevity, in Figure 7 the region of 1800-500 cm-1 of DRIFT spectra was reported, comparing the features of 1:4 wt and 1:10 wt coground system with corresponding PMs and starting materials. The major difference between PMs and coground systems can be noticed in the VIN C=O stretching band (originally at 1713 cm-1). This fact seems to  indicate that the aforementioned disruption of the crystalline lattice mainly leads to changes in the conformation or orientation of this group. 
More information was gathered from Raman spectroscopy.
Raman spectra collected from tablets prepared with physical and coground mixtures of different VIN/PVP-CL wt ratios show bands of both drug and polymer (Fig.8). 
Spectra of physical mixtures are an exact superposition of the two components, all bands being unaffected in frequency or relative intensity, suggesting little or no interaction between VIN and PVP-CL. 
Also in coground mixtures, most bands are unshifted with respect to the pure components, with the exception of some bands in the 1550-1800 cm-1 region, which shows some spectral changes. In the coground mixtures the VIN band at 1610 cm-1, attributed to an aromatic C=C stretching, broadens toward higher frequencies. This broadening is present in all the coground samples and increases with the relative ratio of polymer, being most pronounced in the spectrum of the 1:10 ratio mixture, where a distinct shoulder at 1615 cm-1 can be observed (Fig.8f). Increasing the ratio of polymer in the coground samples also causes the VIN band at 1716, assigned to the C=O stretching, to shift at 1728 cm-1 , together with the appearance of a band at 1774 cm-1, which is clearly observed in the 1:10 mixture. These spectral changes are present exclusively in the coground mixtures, and suggest an interaction between the drug and the polymer which is absent in the physical mixtures. The exact nature of this interaction is difficult to assess, although some hypotheses can be drawn. The absence of any shift in the PVP-CL C=O stretching band at 1668 cm-1 indicates that hydrogen bonding plays little or no role in the polymer-drug interaction.32 This is not surprising since both molecules in their neutral forms contain H-bond acceptors but no donors. 
However it noticeable the shift of the VIN C=O stretching band, that indicates an alteration of the carbonyl environment with respect to the pure substance or to the drug in the physical mixture, similarly to what detected in the FTIR spectra.
Most important, the shift of the VIN aromatic C=C stretching band at 1610 suggests a perturbation of the aromatic moiety of VIN, possibly indicating a hydrophobic interaction between the drug and the polymer, or a polymer-induced change of drug-drug hydrophobic interactions. A similar effect has been reported in the case of the aromatic C=C stretching band of ibuprofen in its mixtures with PVP-CL.33 Despite the absence of a general band broadening, which could be justified by the rigid VIN molecular structure, these changes in the Raman spectra of the coground mixtures could be interpreted as the disruption of the drug crystals by the co-grinding process, which induces an alteration in the C=O and C=C stretching of VIN.
Raman spectroscopy has been also used to evaluate the effect of the co-grinding process on the spatial heterogeneity of the mixtures at microscopic level. The analysis of the Raman maps of tablets prepared from physical and coground mixtures having different drug-polymer ratios showed that VIN is distrubuted much more homogenously in the coground samples than in the physical mixtures (Fig.9).
Solid state NMR has been then used to further study the solid state of the samples and to understand the nature of interactions between components.
 The 13C CP/MAS NMR spectra of solid samples of the pure materials, VIN and PVP-CL, are reported in Figure 10a and b, respectively. Fig. 10a shows a spectrum of VIN with narrow signals indicating the crystalline nature of the sample, whilst fig. 10b shows the spectrum of polymer PVP-CL having broad signals as typical of amorphous substances. NMR spectra of physical mixtures of the aforementioned pure compounds in 1:4 and 1:10 drug-to-polymer wt ratios are shown in Figures 10c and 10d, respectively. Weight ratio of the pure compounds in physical mixtures can be nicely seen, for instance, from the comparison of the signal intensities in carbonyl region of NMR spectra.
In order to establish crystalline or amorphous nature of investigated compounds, the signals corresponding to carbonyl groups has been enlarged (Figure 11) In this part of the spectra it can be nicely seen that the signals corresponding to the C20 atom of VIN inside physical mixtures of both studied wt ratios are still narrow (Figures 11a and b). This observation suggests that the nature of the compound in the physical mixture did not change with respect to the original compound. 
In the case of coground mixture at ratio of polymer PVP-CL and VIN molecules of 1:4, a narrow signal corresponding to the C20 carbon atom of VIN molecule can be still observed (Figure 11c). According to the feature of VIN C=O group in the Raman spectra, the observed signal in this case has a broad shoulder on the right-hand side, suggesting that VIN molecules are partially in an amorphous state. It means that different types of VIN molecules are present in this sample: both crystalline and amorphous forms. When increasing the amount of PVP-CL in the coground sample (1:10 wt system), only broad signals have been observed for carbonyl C20 atom of VIN (Figure 11d). Broad nature of the signals indicates the complete transformation of VIN molecules in an amorphous form at this weight ratio. These findings are in complete agreement with previous DSC and XRD results.  
1H NMR spectra of the parent compounds VIN and PVP-CL as well as physical and coground mixtures (Figure 12) have been also recorded with the purpose of further ascertain the absence of hydrogen bonding in the samples.
In proton spectra, signals belonging to protons involved in hydrogen bonds were not observed, in accordance to the aforementioned Raman data. A spectrum of polymer PVP-CL shows three sharp signals with chemical shifts of 4.19, 3.65 and 1.23 ppm indicating the presence of water molecules in different environments inside the solid sample (Figure 12b). Signals with higher chemical shift (4.19, 3.65) most likely belongs to clusters of pure water somewhere on the surface of the molecule, whilst the signal at  1.23 ppm corresponds to monomeric water.
In order to ascertain the nature of these three sharp signals and if they indeed belong to the water molecules, the sample has been dried (at 40°C for 24h under vacuum). The proton NMR spectrum of dried PVP-CL sample (data not shown), having at the thermogravimetrical analysis (TA Instruments, New Castle, DE, USA) a residual water content < 1%, did not longer exhibit the above mentioned sharp signals.
In the case of VIN we did not observe any sharp signals but only two large humps, originated from signals much lower than those belonging to PVP-CL protons (Figure 12a).
Spectra of physical mixtures (Figures 12c and 12d) and coground mixtures (Figures 12e and 12f) in various proportions of VIN and PCP-CL show only the major water signal at  4.02  or 4.05 or 4.11 ppm.
As a completion of this research, the in vivo bioavailability of the vinpocetine after oral administration in rats of the 1:4 and 1:10 wt coground systems and corresponding physical mixtures was assessed in comparison with a commercial vinpocetine oral formulation (Vimpocetin 5 mg capsules, Pharma). In Figure 13 the plasma concentration profiles are presented whilst the pharmacokinetic parameters are listed in Table 4. 
Both physical mixtures, thanks to the presence of the hydrophilic polymer showed a very little bioavailability enhancement with respect to the drug in the marketed formulation, but the very remarkable increase of drug bioavailability was achieved in the binary systems treated by mechanochemical activation. In particular, 1:4 and 1:10 wt coground systems led to an oral relative bioavailability of 5.1 and 1.8 n comparison to Vimpocetin®, respectively. Further, differently from the commercial formulation having his tmax at 120 min, the plasma profiles of both coground systems revealed their Cmax after only 30 min, testifying that this approach is a viable means to achieve an oral system with faster absorption times. 
Differently from the in vitro performances, the highest oral bioavailability was obtained with the 1:4 wt coground system. This fact is quite interesting and testified that high amounts of crospovidone are not necessary in the formulation to promote an in vivo vinpocetine bioavailability enhancement. This means a reduced drug dilution in the final formulation. Further it gives evidence that the process has a preponderant effect on the in vivo bioavailability.
A possible explanation of the behavior of the 1:10 wt can be found checking the particle size of the coground particles. In Figure 14 the particle volume percentage as a function of the diameter in a log scale of the 1:4 wt system coground for 180 min is depicted and compared to the 1:10 wt system also coground for 180 min. It can be noticed that both samples showed a monomodal distribution, with a peak frequency value of 3.9 m (d 0.5, modal size fraction) in the case of 1:4 wt coground (Fig. 14A), and of about 15.6 m for 1:10 wt coground (Fig. 14B). Further, whilst 1:4 systems exhibited a narrow bell-shaped distribution with most particles ranging from 1.1 to 15 m (d 0.1 - d 0.9, respectively), 1:10 composite distribution is very wide and ranged from 3.3 to 77.9 m. This data attest that increasing the amount of polymer, the particle size raised remarkably and the distribution became significantly wider. Hence, also in this case, in accordance to previous mechanochemical experiences with crospovidone,20,34  the presence of large amount of this polymer can be responsible for the undesired formation of agglomerates, especially with the longest milling times. The presence of crospovidone, that contains 5% water content at the time of manufacture,33 may cause the formation of large agglomerates, with a phenomenon probably similar to a wet granulation process. 
These different dimensions of the coground samples can give reason for the differences in the in vivo performances. A possible explanation is hence that the larger agglomerates found in the coground containing high amounts of PVP-CL are responsible for the unexpected reduced in vivo performance. 
Moreover, the unexpected lesser bioavailability of the 1:10 wt coground can be due to biological and hydrodynamic conditions: the little volume (2ml) administered to the animals is probably not enough to efficiently disperse the entire dose in a 1:10 wt ratio with the polymer. Conversely, the 1:4 wt sample, having less amount of powder can be dispersed, and thus absorbed easier. 
Another possible explanation is the presence of a thin stagnant layer originated by PVP-CL particle aggregation and adhesion on the intestine wall. In particular in previous investigations,35clusters between intestinal mucus and ground polymeric particles were noticed. In this case, the difference in the thickness of stagnant layer, in layer viscosity and in the interaction inside these clusters due to different amounts of crospovidone can explain the different absorption across the intestine membrane, and thus the different plasma profiles .
Aging studies 
The drug solid state in the selected coground samples (1:4 and 1:10 wt) was studied by repeating the DSC analyses every 4 months for a period of 1 year (data not shown). These curves are completely superimposable to that of freshly prepared samples, attesting the stability of the activated status (completely amorphous in the 1:10 wt and partially nanocrystalline in the case of 1:4 wt). Once embedded in the polymeric network, as clearly visible in TEM images reported in Fig.6a,  the drug is stabilized in the metastable amorphous or nanocrystalline form. It is reasonable that the recrystallization is prevented by restricting drug mobility thanks to the aforementioned interactions with the polymeric carrier and/or to the antiplasticizing effect of the polymer, that increases the viscosity of the binary systems and thereby decreases the diffusion of drug molecules necessary to form the lattice.36 In the case of PVP-CL, the stabilizing potential has been reported in several cogrinding experiences.20,37 The stability of the nanocrystalline/amorphous state of the drug is further facilitated by the energetic contribution of the mechanochemical activation. 

Conclusions 
Vinpocetine was successfully coground in a planetary mill, which made possible an enhancement of bioavailability through a solid state activation. The effect of the amount of crospovidone and of the milling time on vinpocetine activation in coground mixtures was statistically investigated. The drug release rate resulted directly related to the amount of polymer and milling time. In fact, as these variables increased, the drug was progressively transformed into an amorphous and/or nanocrystalline state extremely favorable for the in vitro dissolution. A multidisciplinary approach employed in the study of the sample permitted an extensive characterization of the changes induced on the drug solid state after mechanochemical activation. These analyses revealed the perturbation of the VIN carbonyl environment as a results of the disruption of the crystalline lattice, the absence of hydrogen bonding between components and the insurgence of hydrophobic interaction between crospovidone and VIN. Further the characterizations attested that the activated drug solid state was homogeneously present n the coground systems and was stable for at least one year.
A comparison with an oral commercial formulation (Vimpocetin®) revealed that the coground were able to enhance the oral bioavailability of 5 folds. 
It can be concluded that the solid state mechanochemical process in presence of micronized crospovidone is a viable means to improve the oral bioavailability of vinpocetine through its transformation into a highly soluble-readily absorbable form.
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